A clinical trial of TEV-48125 versus Placebo for the Preventive Treatment of Chronic Migraine

Registry ID

EUCTR2015-004549-23

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Start date

2016-09-05

Last update

2026-08-16

Conditions

• Chronic Migraine

Summary

• to demonstrate the efficacy of 2 dose regimens of TEV-48125, as assessed by the decrease in the monthly average number of headache days of at least moderate severity during the 12-week period after the 1st dose of study drug relative to the baseline period • to evaluate the safety and tolerability of 2 dose regimens of TEV-48125 in the preventive treatment of CM

Locations

• , , Spain
• , , Czechia
• , , Finland
• , , Germany
• , , Denmark

Related clinical trials

• Responding With Evidence and Access for Childhood Headaches
• The RECLAIM Study.
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
• Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
• BOTOX® vs. XEOMIN® for Chronic Migraine
• Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)

View on source registry